Philip Morris acquires OtiTopic, a company that develops inhaled medications for people at high risk of myocardial infarction. OtiTopic has patented ASPRIHALE, an acetylsalicylic acid inhalation drug. The drug is currently undergoing clinical trials and is scheduled to file for FDA approval in 2022. Terms of the deal were not disclosed.